Clinical trials


Durvalumab (MEDI4736) After chemoRadioTherapy for NSCLC patients – a phase II translational and biomarker study investigating PDL1 positive and negative patients More information	Nivolumab and Ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma – a phase II randomised clinical and translational trial More information
	NorPACT-2
Immunotherapy combined with extensive radiotherapy for the treatment of stage IV non-small cell lung cancer (COM-IT-2) – a phase II randomised clinical and translational trial More information	Norwegian Pancreatic Cancer Trial (NorPACT)-2: Liquid biopsies and blood-based biomarkers (https://www.ous-research.no/ pancreaticcancer)

Scroll to top

Recent publications

Nymoen HM, Alver TN, Horndalsveen H, Eide HA, Bjaanæs MM, Brustugun OT, Grønberg BH, Haakensen VD, Helland Å (2024)
Thoracic radiation in combination with erlotinib-results from a phase 2 randomized trial
Front Oncol, 14, 1412716
DOI 10.3389/fonc.2024.1412716, PubMed 39148905

Thunold S, Hernes E, Farooqi S, Öjlert ÅK, Francis RJ, Nowak AK, Szejniuk WM, Nielsen SS, Cedres S, Perdigo MS, Sørensen JB, Meltzer C, Mikalsen LTG, Helland Å, Malinen E, Haakensen VD (2024)
Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
Eur J Nucl Med Mol Imaging (in press)
DOI 10.1007/s00259-024-06853-0, PubMed 39133306

Bjørgo E, Fagereng GL, Russnes HG, Smeland S, Taskén K, Helland Å (2024)
Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare
Acta Oncol, 63, 487-490
DOI 10.2340/1651-226X.2024.24954, PubMed 38910311

More publications

NorPACT-2